ASCO 2024: Lung cancer roundup

Share :
Published: 4 Jun 2024
Views: 154
Rating:
Save
Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Dr Luis Raez gives his thoughts on key studies in lung cancer from ASCO 2024.

He covers the following studies:

CROWN: 5 year progression-free survival and safety from study into lorlatinib versus crizotinib in treatment-naïve patients with advanced ALK positive non-small cell lung cancer.
ADRIATIC: Durvalumab as consolidation treatment for patients with limited-stage small-cell lung cancer.
LAURA: Osimertinib after definitive chemoradiotherapy in patients with unresectable stage III epidermal growth factor receptor-mutated non-small cell lung cancer.